Class III Beta-tubulin Expression and in Vitro Resistance to Microtubule Targeting Agents

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Dec 24

PMID 20029418

Citations 78

Authors

C Stengel

S P Newman

M P Leese

B V L Potter

M J Reed

A Purohit

Affiliations

Soon will be listed here.

Abstract

Background: Class III beta-tubulin overexpression is a marker of resistance to microtubule disruptors in vitro, in vivo and in the clinic for many cancers, including breast cancer. The aims of this study were to develop a new model of class III beta-tubulin expression, avoiding the toxicity associated with chronic overexpression of class III beta-tubulin, and study the efficacy of a panel of clinical and pre-clinical drugs in this model.

Methods: MCF-7 (ER+ve) and MDA-MB-231 (ER-ve) were either transfected with pALTER-TUBB3 or siRNA-tubb3 and 24 h later exposed to test compounds for a further 96 h for proliferation studies. RT-PCR and immunoblotting were used to monitor the changes in class III beta-tubulin mRNA and protein expression.

Results: The model allowed for subtle changes in class III beta-tubulin expression to be achieved, which had no direct effect on the viability of the cells. Class III beta-tubulin overexpression conferred resistance to paclitaxel and vinorelbine, whereas downregulation of class III beta-tubulin rendered cells more sensitive to these two drugs. The efficacy of the colchicine-site binding agents, 2-MeOE2, colchicine, STX140, ENMD1198 and STX243 was unaffected by the changes in class III beta-tubulin expression.

Conclusion: These data indicate that the effect of class III beta-tubulin overexpression may depend on where the drug's binding site is located on the tubulin. Therefore, this study highlights for the first time the potential key role of targeting the colchicine-binding site, to develop new treatment modalities for taxane-refractory breast cancer.

Citing Articles

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.

Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S Sci Rep. 2025; 15(1):4294.

PMID: 39905117 PMC: 11794704. DOI: 10.1038/s41598-024-82218-9.

Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening.

Zhao D, Deshpande R, Wu K, Tyagi A, Sharma S, Wu S Neoplasia. 2024; 60:101100.

PMID: 39671912 PMC: 11699798. DOI: 10.1016/j.neo.2024.101100.

Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer models.

Horn L, Lind H, Fousek K, Qin H, Rajabian N, Angstadt S J Exp Clin Cancer Res. 2024; 43(1):318.

PMID: 39639338 PMC: 11619435. DOI: 10.1186/s13046-024-03240-3.

β3 accelerates microtubule plus end maturation through a divergent lateral interface.

Wood L, Moore J bioRxiv. 2024; .

PMID: 39071388 PMC: 11275713. DOI: 10.1101/2024.07.17.603993.

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.

Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S bioRxiv. 2024; .

PMID: 38895265 PMC: 11185620. DOI: 10.1101/2024.06.04.596911.

References

Leese M, Leblond B, Newman S, Purohit A, Reed M, Potter B . Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates. J Steroid Biochem Mol Biol. 2005; 94(1-3):239-51. DOI: 10.1016/j.jsbmb.2005.01.005. View

Ranganathan S, McCauley R, Dexter D, Hudes G . Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. Br J Cancer. 2001; 85(5):735-40. PMC: 2364133. DOI: 10.1054/bjoc.2001.1956. View

Leese M, Hejaz H, Mahon M, Newman S, Purohit A, Reed M . A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents. J Med Chem. 2005; 48(16):5243-56. DOI: 10.1021/jm050066a. View

Joe P, Banerjee A, Luduena R . The roles of cys124 and ser239 in the functional properties of human betaIII tubulin. Cell Motil Cytoskeleton. 2008; 65(6):476-86. DOI: 10.1002/cm.20274. View

Theodorakis N, Cleveland D . Physical evidence for cotranslational regulation of beta-tubulin mRNA degradation. Mol Cell Biol. 1992; 12(2):791-9. PMC: 364304. DOI: 10.1128/mcb.12.2.791-799.1992. View

Correnti M, Cavazza M, Guedez N, HERRERA O . Expression of the multidrug-resistance (MDR) gene in breast cancer. J Chemother. 1995; 7(5):449-51. DOI: 10.1179/joc.1995.7.5.449. View

Lamendola D, Duan Z, Penson R, Oliva E, Seiden M . beta tubulin mutations are rare in human ovarian carcinoma. Anticancer Res. 2003; 23(1B):681-6. View

Seve P, Dumontet C . Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol. 2008; 9(2):168-75. DOI: 10.1016/S1470-2045(08)70029-9. View

Mhaidat N, Thorne R, de Bock C, Zhang X, Hersey P . Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels. FEBS Lett. 2007; 582(2):267-72. DOI: 10.1016/j.febslet.2007.12.014. View

10.

Hari M, Yang H, Zeng C, Canizales M, Cabral F . Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton. 2003; 56(1):45-56. DOI: 10.1002/cm.10132. View

11.

Tsurutani J, Komiya T, Uejima H, Tada H, Syunichi N, Oka M . Mutational analysis of the beta-tubulin gene in lung cancer. Lung Cancer. 2001; 35(1):11-6. DOI: 10.1016/s0169-5002(01)00291-4. View

12.

Urano N, Fujiwara Y, Doki Y, Kim S, Miyoshi Y, Noguchi S . Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol. 2006; 28(2):375-81. View

13.

Newman S, Foster P, Stengel C, Day J, Ho Y, Judde J . STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res. 2008; 14(2):597-606. DOI: 10.1158/1078-0432.CCR-07-1717. View

14.

Lowe J, Li H, Downing K, Nogales E . Refined structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol. 2001; 313(5):1045-57. DOI: 10.1006/jmbi.2001.5077. View

15.

Risinger A, Jackson E, Polin L, Helms G, LeBoeuf D, Joe P . The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res. 2008; 68(21):8881-8. PMC: 2727482. DOI: 10.1158/0008-5472.CAN-08-2037. View

16.

Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A . Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer. 2007; 120(10):2078-85. DOI: 10.1002/ijc.22557. View

17.

Linn S, Giaccone G, van Diest P, Blokhuis W, van der Valk P, van Kalken C . Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol. 1995; 6(7):679-85. DOI: 10.1093/oxfordjournals.annonc.a059284. View

18.

Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D . The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res. 2005; 65(6):2397-405. DOI: 10.1158/0008-5472.CAN-04-3065. View

19.

Noguchi S . Predictive factors for response to docetaxel in human breast cancers. Cancer Sci. 2006; 97(9):813-20. PMC: 11158941. DOI: 10.1111/j.1349-7006.2006.00265.x. View

20.

Kamath K, Wilson L, Cabral F, Jordan M . BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem. 2005; 280(13):12902-7. DOI: 10.1074/jbc.M414477200. View